A double-blind, placebo-controlled, randomized trial with anti-TNFα Ab infliximab in 60 patients with major depression showed an association between baseline levels of the inflammatory marker CRP and the response to infliximab [140]. The gene discussed is CRP; the disease is major depressive disorder.